Pharmaceutical Investing Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018
Eloxx Pharmaceuticals Announces FDA Grant of Orphan-Drug Designation for Investigational Drug ELX-02 for Treatment of Cystinosis
Pharmaceutical Investing Proteostasis Therapeutics Announces FDA Grants Orphan Drug Designation for PTI-428 in Cystic Fibrosis
Pharmaceutical Investing Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis
Pharmaceutical Investing Corbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical Update
Pharmaceutical Investing Santhera Obtains Worldwide Exclusive License from Polyphor to Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis
Pharmaceutical Investing Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design
Pharmaceutical Investing Corbus Gets Patent Covering Use of Anabasum for the Treatment of Rare Fibrotic Diseases
Athena Reports Results From 2024 Prospecting Program at Excelsior Springs, Outlines New Targets, and Expands Land Package
Juggernaut Further Increases Oversubscribed Financing to $10,329,735 Due to Strong Demand from Institutions and Accredited Investors -- Dr. Quinton Hennigh Technical Advisor
Cygnus Metals to Present at the Precious Metals & Critical Minerals Hybrid Investor Conference on May 22nd
Skyharbour and JV Partner Orano to Commence Extensive Summer 2025 Drilling Program at Preston Uranium Project
